Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

AstraZeneca Initiates CLARITY-Gastric 02 Phase III – Sonesitatug Vedotin Combo Triggers $45 Million Milestone from KYM Biosciences

Fineline Cube Mar 11, 2026
Company Deals

GSK Licenses Linerixibat to Alfasigma for $300 Million Upfront – IBAT Inhibitor Targets PBC Pruritus with $690 Million Total Deal Value

Fineline Cube Mar 10, 2026
Company Deals Drug

Novo Nordisk Settles with Hims & Hers – Ozempic Wegovy Distribution Deal Ends Patent Litigation, Eliminates Compounded GLP-1 Advertising

Fineline Cube Mar 10, 2026
Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Fineline Cube Mar 9, 2026
Company Deals

Boan Biotech Partners with DP Technology on AI4S Drug Discovery – Antibody, ADC, and TCE Pipeline Acceleration

Fineline Cube Mar 6, 2026
Policy / Regulatory

FDA Streamlines Biosimilar Development – New Guidance Cuts PK Study Costs by 50%, Accelerates Path to Market

Fineline Cube Mar 10, 2026
Company Drug

Pfizer’s Tilrekimig Hits Phase 2 Primary Endpoint – IL-4/IL-13/TSLP Trispecific Shows 52% EASI-75 Response in Atopic Dermatitis

Fineline Cube Mar 11, 2026
Company Drug

FDA Accepts ENHERTU sBLA with Priority Review – HER2 ADC Seeks Early Breast Cancer Approval with 53% Recurrence Risk Reduction

Fineline Cube Mar 11, 2026
Company Deals

Boehringer Ingelheim Partners with Phenomic AI to Target Stroma-Rich Cancers

Fineline Cube Nov 30, 2023

Boehringer Ingelheim (BI), a German pharmaceutical company, has entered into a partnership with Canada’s Phenomic...

Company Drug

Jiangsu Hengrui Receives NMPA Approval for Esophageal Cancer and Breast Cancer Clinical Trials

Fineline Cube Nov 30, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received approval from the National Medical Products...

Company Drug

Asieris Pharmaceuticals’ Hexvix for Bladder Cancer Accepted for Review by China’s NMPA

Fineline Cube Nov 30, 2023

Asieris Pharmaceuticals (SHA: 688176), a specialist in urogenital cancer based in China, has announced that...

Company Drug

Jiangxi Jemincare’s KRAS Inhibitor Earns Breakthrough Designation from China’s CDE for NSCLC

Fineline Cube Nov 30, 2023

The China Center for Drug Evaluation (CDE) website has indicated that Jiangxi Jemincare Group’s proprietary...

Company Deals

Eli Lilly Partners with Prism BioLab to Discover Peptide-Mimicking Small Molecule Inhibitors

Fineline Cube Nov 30, 2023

Eli Lilly and Company (NYSE: LLY) has entered into a partnership with Japan-based biotechnology firm...

Company Drug

Roche’s Mosunetuzumab and AnHeart’s Taletrectinib Poised for Priority Review in China

Fineline Cube Nov 30, 2023

The China Center for Drug Evaluation (CDE) website has indicated that Roche’s (SWX: ROG) Lunsumio...

Policy / Regulatory

China’s CDE Expands Market Approval Services with Two New Regional Windows

Fineline Cube Nov 30, 2023

The China Center for Drug Evaluation (CDE) has announced the establishment of two additional external...

Company Drug

Sinocelltech’s PD-1 Inhibitor SCT-I10A for HNSCC Accepted for NMPA Review

Fineline Cube Nov 30, 2023

Sinocelltech Group Ltd (SHA: 688520), a Chinese biopharmaceutical company, has announced that its market approval...

Company Deals

Bosscome Science & Technology Secures Series A Funding for Precision Medical Navigation Systems

Fineline Cube Nov 30, 2023

Bosscome Science & Technology, a Chongqing-based developer of integrated optical and magnetic navigation systems, has...

Company Policy / Regulatory

NMPA Approves TINGSN Technology’s Disposable Intracardiac Ultrasound Diagnostic Catheter

Fineline Cube Nov 30, 2023

The National Medical Products Administration (NMPA) has granted market approval to TINGSN Technology, a China-based...

Company Drug

Everest Medicines’ Nefecon NDA for IgAN Accepted for Review in South Korea

Fineline Cube Nov 30, 2023

Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that the New Drug Application...

Company Digital

ClouDr Partners with Yangtze River Pharmaceutical to Digitize Chronic Disease Marketing

Fineline Cube Nov 30, 2023

Hangzhou Kang Ming Information Technology Co., Ltd, trading as “ClouDr” (HKG: 9955), has entered into...

Company Policy / Regulatory

CAR T-Cell Therapy Stocks Plunge as FDA Investigates Cancer Reports Linked to Treatments

Fineline Cube Nov 30, 2023

Shares of Chimeric Antigen Receptor (CAR) T cell therapy companies plummeted on November 28, 2023,...

Company Deals

Pfizer Enters Strategic Alliance with Guangdong Government to Boost Biomedicine R&D

Fineline Cube Nov 29, 2023

Pfizer (NYSE: PFE), the US pharmaceutical powerhouse, has signed a strategic memorandum of understanding with...

Company Deals

Bayer Partners with Hurdle to Launch Saliva-Based Age Tests in Global E-Commerce

Fineline Cube Nov 29, 2023

Bayer (ETR: BAYN), the German multinational, has announced a strategic collaboration to globally distribute Hurdle’s...

Company Drug

Merck’s V116 Pneumococcal Vaccine Shows Promising Data Against Pfizer’s Prevnar 20

Fineline Cube Nov 29, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has unveiled new data from a late-stage trial...

Policy / Regulatory

China’s Pharma Distribution Market Grows Steadily in 2022, Driven by Retail Sales Surge

Fineline Cube Nov 29, 2023

The Ministry of Commerce (MofCOM) has released its annual statistical review of China’s pharmaceutical distribution...

Company Deals

BMS and Avidity Biosciences Join Forces on $2.2 Billion Cardiology Antibody Oligonucleotide Conjugate Deal

Fineline Cube Nov 29, 2023

Bristol Myers Squibb (BMS, NYSE: BMY) has announced a strategic partnership with Avidity Biosciences (NASDAQ:...

Company Deals

Blue Sail Medical and China National Medical Device Forge Strategic Partnership for Growth

Fineline Cube Nov 29, 2023

Blue Sail Medical Co., Ltd (SHE: 002382), a prominent player in China’s medical device sector,...

Company

Alibaba Health Reports 12.7% Revenue Growth in H1 2023, Driven by Pharmaceutical and Digital Services

Fineline Cube Nov 29, 2023

Alibaba Health Information Technology Ltd (HKG: 0241), based in China, has released its financial results...

Posts pagination

1 … 403 404 405 … 633

Recent updates

  • Pfizer’s Tilrekimig Hits Phase 2 Primary Endpoint – IL-4/IL-13/TSLP Trispecific Shows 52% EASI-75 Response in Atopic Dermatitis
  • FDA Accepts ENHERTU sBLA with Priority Review – HER2 ADC Seeks Early Breast Cancer Approval with 53% Recurrence Risk Reduction
  • J&J Files TECVAYLI Line Extension with EMA – BCMA Bispecific Seeks Earlier Use in Second-Line Multiple Myeloma
  • HighTide Therapeutics’ HTD1801 NDA Accepted by NMPA – First-in-Class AMPK/NLRP3 Dual-Target Drug for Type 2 Diabetes
  • AstraZeneca Initiates CLARITY-Gastric 02 Phase III – Sonesitatug Vedotin Combo Triggers $45 Million Milestone from KYM Biosciences
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Pfizer’s Tilrekimig Hits Phase 2 Primary Endpoint – IL-4/IL-13/TSLP Trispecific Shows 52% EASI-75 Response in Atopic Dermatitis

Company Drug

FDA Accepts ENHERTU sBLA with Priority Review – HER2 ADC Seeks Early Breast Cancer Approval with 53% Recurrence Risk Reduction

Company Drug

J&J Files TECVAYLI Line Extension with EMA – BCMA Bispecific Seeks Earlier Use in Second-Line Multiple Myeloma

Company Drug

HighTide Therapeutics’ HTD1801 NDA Accepted by NMPA – First-in-Class AMPK/NLRP3 Dual-Target Drug for Type 2 Diabetes

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.